Samsung Engineering, one of the world’s leading engineering, procurement, construction, and project management (EPC&PM) companies, has announced that it has won an early work contract from global life science company Sartorius, for the first construction phase of a plant in Songdo, Incheon Korea, that will manufacture products and consumables used for the production of biopharmaceuticals.

The contract amount is approximately KRW 78.4 billion, and Samsung Engineering plans to carry out the initial construction work of the project, such as site suspension, pile construction, foundation work, and permit support etc. by the end of next year.

Founded in Germany 1870, the Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry and had announced its plans for the large-scale expansion project in Korea last year.

The plant, to be built in the Incheon Free Economic Zone in Songdo, Incheon, will be a facility for the manufacture of products such as sterile bags, cell culture media and membrane filters. There will also be facilities for R&D and Service, as well as a training and application center.

Samsung Engineering implemented from the beginning of the project their ‘FEED to EPC strategy’ and successfully carried out basic engineering and detailed engineering work, gaining the trust of the client. In addition, proposing to the client a differentiated construction strategy based on rich bio product experience and technological competitiveness in the Songdo region had a great impact on winning this order.

Hong Namkoong, President and CEO, Samsung Engineering said, "Samsung Engineering possesses the technology and know-how through rich project experience in the bio field."

"We will put all our efforts to successfully carry out this initial task to gain trust from the client leading to the main construction order," added Namkoong.